ArticleNature metabolism2026
FXR-YAP signalling maintains biliary epithelial cell identity and preserves liver homeostasis.
Article in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FXR's double life in bile ducts.Nature metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bile acids (BAs) flow through ducts lined by biliary epithelial cells (BECs), which preserve ductal integrity and liver homeostasis. Failure of this barrier causes BA accumulation in the liver parenchyma, and ultimately fibrosis. Here we show that BECs safeguard biliary barrier integrity and restrain BA-induced fibrogenesis through a cell-intrinsic mechanism involving farnesoid-X-receptor (FXR)-YAP signalling. Using a combination of mouse genetics, computational analysis and human samples, we show that BECs express FXR, which transcriptionally activates YAP to maintain their adhesion, thereby preventing BA efflux and subsequent FXR-dependent hepatic stellate cell activation and fibrosis in BA-dysregulated liver disease models. Genetic ablation of FXR or YAP in mouse BECs triggers β-catenin activation, mesenchymal-like conversion and BEC proliferation, promoting fibrosis-to-cirrhosis progression. Diminished FXR-YAP signalling in human BECs also parallels fibrosis severity. Consistently, obeticholic acid worsens fibrogenesis in mice with FXR-depleted BECs. Thus, BAs reprogram BECs into active guardians of tissue integrity via FXR-YAP-β-catenin signalling, preserving biliary identity and maintaining liver homeostasis.
Indexed as
Identifiers
42049952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.